Contribution of reactive oxygen species to the anticancer activity of aminoalkanol derivatives of xanthone Daniel SypniewskiNatalia SzkaradekIlona Bednarek PRECLINICAL STUDIES Open access 08 November 2017 Pages: 355 - 369
Cyclodextrin polymers as nanocarriers for sorafenib Valentina GiglioMaurizio VialeGraziella Vecchio PRECLINICAL STUDIES 08 November 2017 Pages: 370 - 379
ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors Mark C. de GooijerLevi C. M. BuilOlaf van Tellingen PRECLINICAL STUDIES 17 November 2017 Pages: 380 - 387
LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice Kazim SahinMehmet TuzcuIbrahim H. Ozercan PRECLINICAL STUDIES 15 November 2017 Pages: 388 - 395
The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing’s sarcoma cell line Christian MarxLisa Marx-BlümelJürgen Sonnemann PRECLINICAL STUDIES 18 November 2017 Pages: 396 - 406
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors Neeraj GuptaSteven ZhangDale R. Shepard PHASE I STUDIES Open access 21 September 2017 Pages: 407 - 415
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer Shumei KatoDenis L. JardimDavid S. Hong PHASE I STUDIES 19 October 2017 Pages: 416 - 423
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors Tomohiro NishinaShunji TakahashiToshihiko Doi PHASE I STUDIES 30 September 2017 Pages: 424 - 434
Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer Priyanka BhatejaAfshin DowlatiNeelesh Sharma PHASE I STUDIES 02 October 2017 Pages: 435 - 441
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results Dana B. CardinLaura W. GoffNipun Merchant PHASE I STUDIES 09 October 2017 Pages: 442 - 450
A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC) Pedro BarataMatthew CooneyJorge A. Garcia PHASE II STUDIES 23 February 2018 Pages: 451 - 457
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer Laura GrahamKalyan BandaDana E. Rathkopf PHASE II STUDIES 06 March 2018 Pages: 458 - 467
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study Xavier García del MuroJoan MaurelJavier Martín Broto PHASE II STUDIES 12 March 2018 Pages: 468 - 475
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial Emiliano CalvoAnalia AzaroMargaret von Mehren PHASE III STUDIES 27 November 2017 Pages: 476 - 486
Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases Sumimasa NagaiKeiya Ozawa PHASE III STUDIES 17 February 2018 Pages: 487 - 495
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin Hyungwoo ChoChanghoon YooBaek-Yeol Ryoo SHORT REPORT 01 December 2017 Pages: 496 - 502
Everolimus induced mood changes in breast cancer patients: a case-control study Olivier MirAlexandre SalvadorRaphaël Gaillard SHORT REPORT 18 December 2017 Pages: 503 - 508
Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report Kenta OgawaJiro ItoNobuyuki Katakami SHORT REPORT 16 January 2018 Pages: 509 - 512
Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report Michael W. van KalleveenMaudy WalravenMathijs P. Hendriks SHORT REPORT 20 February 2018 Pages: 513 - 516
A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine Akihiko OzakiMorihito TakitaTetsuya Tanimoto SHORT REPORT 08 March 2018 Pages: 517 - 522